Search Results

synthetic DNA using its silicon platform, today announced it has launched Revelar Biotherapeutics, Inc

Morgan Healthcare Conference Neurocrine Biosciences, Inc.'s Director Stephen A.

Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists "The increasing investigations into animal models and ongoing clinical trials using these unimolecular dual and triagonists are included

Dive into the exciting world of incorporating machine learning, innovative biophysical methods, and medicinal Register now for the GPCR Drug Discovery Conference and unlock incredible savings of $200 using the Let's dive in and make the most of this incredible opportunity! GLP-1/FGF21 dual agonist ZT-003 shows promising results for metabolic disorders INDIGO Biosciences, INC

Adhesion GPCRs The Posttraumatic Increase in the Adhesion of GPCR EMR2/ ADGRE2 to Circulating Neutrophils and structural basis of GPR84 signaling Advancements in Precision Medicine: Superluminal Medicines Inc

The GPCR rocket is all fueled and ready to blast off into a galaxy of incredible advancements, now powered Targeted Antibody Therapeutics Using Generative AI Zombie Fungi Hijack Hosts’ Brains GPCR Therapeutics, Inc

This week's highlight includes congrats to: Gabriele Kockelkoren, Dr. Confirmed speakers include Drs. receptors-mediated adenylyl cyclase/ cyclic AMP signaling pathway The non-nutritive sweetener sucralose increases receptors to treat cancer and inflammation AVROBIO and Tectonic Therapeutic Announce Merger Trevena Inc

This week's highlight includes congrats to: Drs. GPCRs by signing up for a Premium Membership to watch all the material recorded at our previous events, including Receptor Signaling Industry News Addex Gets Creative To Secure Funding And Its Future Reunion Neuroscience Inc

Companies already confirmed to attend include: Abalone Bio · AbbVie · Biagon · Biolexis Therapeutics Cyclic Peptides & Allosteric Modulators Nine or more presentations on non-small molecule approaches — including Companies presenting include Skymab Biotherapeutics, Confo Therapeutics, GSK, Metaphore Biotechnologies

Food and one drink ticket included. Cash bar available. Register your spot here. across mammalian, insect, and bacterial expression systems with high-resolution cryo-EM capabilities, including Today, their catalogue includes over 1,000 functional assays representing more than 550 GPCR and other Cafe, 105 Huntington Ave, Boston, MA (A two-minute walk from The Colonnade) Food and one drink ticket included

Explore the library ➤ Five Live GPCR Masterclasses Before Summer All included in Premium , each one a

GPCR community live on April 16 — one of 12+ Masterclasses planned for 2026, all included in Premium. Learn More ➤ This live session with recording available as well as all masterclasses are now included This Week in Premium Premium Members are reading 18 publications this week, including a review on GRK

T This is one of 12+ live Masterclasses planned for 2026 — all included in Premium, each one a direct live discussion ➤ This live session with recording available as well as all masterclasses are now included live discussion ➤   This live session with recording available as well as all masterclasses are now included spectrometry dataset comprising 3,384 small-molecule ligands across approximately 400 transmembrane proteins, including This Week in Premium Premium Members are reading 15 new publications this week, including a quantitative

This live session with recording available as well as all masterclasses are now included in Premium. Organoid models incorporate cellular architecture that affects receptor signaling and pathway integration This live session with recording available as well as all masterclasses are now included in Premium. This Week in Premium This is what Premium Members are reading this week: 20 classified papers including Premium membership includes live masterclasses, full replays, and access to the complete Masterclass

This week in Premium Premium Members are reading 17 publications this week, including new findings on

Binding increases while function falls. Not because one is incorrect—but because each is observing a different population of receptor states. Kenakin walks through a cannabinoid modulator that increases agonist binding while reducing signaling In orthosteric systems, the curve reflects physical displacement: increasing concentrations of a competing displace an allosteric ligand in a low G-protein environment but succeeded when G-protein levels were increased

These efforts are supported by characterization approaches that include knockout/knockdown testing, endogenous

That model was useful, but it was also incomplete. Two examples of this include the opioid and chemokine GPCR receptors. Viruses including HIV and SARS-CoV-2 exploit or modulate GPCR signaling to facilitate cell entry, immune Eurofins DiscoverX has developed an extensive platform of GPCR functional assays — including β -arrestin multi-pathway functional assays , phenotypic integration, and rigorous pharmacokinetic correlation are now increasingly

Practical strategies include: Using known controls (e.g., ATP or carbachol) to define maximal signal Common PK deal breakers include: poor solubility preventing absorption rapid clearance eliminating exposure Kenaking reveals how experienced pharmacologists turn repeated failures into increasingly powerful insights

Transfected cells were treated with increasing concentrations of CELT-463 or CELT-464 in the presence Increasing concentrations of the competitor compounds were added and the signal measured. expressing signal peptide-nanoluc®-A2AAR were treated with 50nM CELT-463 or CELT-464 in the presence of increasing Selective or promiscuous, agonists or antagonists were for all 4 Adenosine Receptors were included in

Kenakin outlines a practical solution: use a potency metric that incorporates both efficacy and EC₅₀ If confidence intervals include zero, selectivity is not statistically significant. In a world of increasingly complex GPCR modulation, these distinctions are not academic.

They play a role in various pathologies, including neurological, oncological, degenerative, metabolic Interest in this receptor has surged recently due to its involvement in several inflammatory pathologies , including At Celtarys , we employ various conjugation techniques , including our proprietary semi-combinatorial

Increasing complexity. And slowly, strategic focus weakens . Instead, momentum becomes inconsistent. Teams feel busy, but outcomes feel less decisive. Capital efficiency decreases not because spending increases, but because allocation becomes less sharp When strategic friction increases, confidence decreases. This is where credibility increases.

If you want structured, year-round access to Terry’s full library — including advanced lectures, archived

Each program appears to increase optionality and reduce risk. 👉 This is where strategic overload begins 👉 The story shifts from decisive execution to optional exploration 👉 The perceived execution risk increases initiatives, demonstrating alignment becomes harder. 👉 Strategic overload does not make a company look incompetent

All masterclasses — past and upcoming — are included with Premium Membership. GPCR–lipid raft associations and the expanding therapeutic landscape of extra-oral bitter taste receptors, including Interpretation risk is increasing. Dr.

announced a strategic partnership with Eurofins DiscoverX , a global leader in GPCR product solutions including Their cell-based assays support a wide range of mechanisms of action, including cAMP accumulation, β-arrestin

Orthosteric antagonists remain theoretically unlimited  — competition continues as concentration increases becomes critical in both screening strategy and therapeutic positioning As ligand diversity expands — including

Each course page includes a short trailer, defined learning outcomes, and explicit take-home messages All courses remain included in Premium Membership. Submissions are welcome across formats including Original Research, Reviews, Methods, Perspectives, Hypothesis GPCR University courses — now included in Premium. Reduce external training spend while increasing scientific depth.

👉 Strong biotech startups do not fail because the science is weak or the team is incapable. Meetings increase. Slides improve. Activity intensifies. Activity increases, but clarity erodes , and the company becomes reactive instead of intentional. Scientific nuance starts to feel inconvenient. strategically settled. 4️⃣ They protect decision quality under pressure. 👉 As fundraising intensity increases